Activation of double-stranded RNA-dependent protein kinase inhibits proliferation of pancreatic β-cells

Biochem Biophys Res Commun. 2014 Jan 17;443(3):814-20. doi: 10.1016/j.bbrc.2013.12.051. Epub 2013 Dec 14.

Abstract

Double-stranded RNA-dependent protein kinase (PKR) is revealed to participate in the development of insulin resistance in peripheral tissues in type 2 diabetes (T2DM). Meanwhile, PKR is also characterized as a critical regulator of cell proliferation. To date, no study has focused on the impact of PKR on the proliferation of pancreatic β-cells. Here, we adopted insulinoma cell lines and mice islet β-cells to investigate: (1) the effects of glucolipotoxicity and pro-inflammatory cytokines on PKR activation; (2) the effects of PKR on proliferation of pancreatic β-cells and its underlying mechanisms; (3) the actions of PKR on pro-proliferative effects of IGF-I and its underlying pathway. Our results provided the first evidence that PKR can be activated by glucolipitoxicity and pro-inflammatory cytokines in pancreatic β-cells, and activated PKR significantly inhibited cell proliferation by arresting cell cycle at G1 phase. Reductions in cyclin D1 and D2 as well as increases in p27 and p53 were associated with the anti-proliferative effects of PKR, and proteasome-dependent degradation took part in the reduction of cyclin D1 and D2. Besides, PKR activation abrogated the pro-proliferative effects of IGF-I by activating JNK and disrupting IRS1/PI3K/Akt signaling pathway. These findings indicate that the anti-proliferative actions of PKR on pancreatic β-cells may contribute to the pathogenesis of T2DM.

Keywords: Diabetes; Glucolipitoxicity; PKR; Pancreatic β-cell; Pro-inflammatory cytokine; Proliferation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Cycle Checkpoints / drug effects
  • Cell Cycle Checkpoints / genetics
  • Cell Line
  • Cell Proliferation / drug effects
  • Cyclin D1 / metabolism
  • Cyclin D2 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p27 / metabolism
  • Cytokines / metabolism
  • Enzyme Activation / drug effects
  • G1 Phase / drug effects
  • G1 Phase / genetics
  • Glucose / toxicity
  • Inflammation Mediators / metabolism
  • Insulin-Like Growth Factor I / pharmacology
  • Insulin-Secreting Cells / cytology*
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / enzymology*
  • Lipids / toxicity
  • Mice
  • Tumor Suppressor Protein p53 / metabolism
  • Up-Regulation / drug effects
  • eIF-2 Kinase / metabolism*

Substances

  • Cyclin D2
  • Cytokines
  • Inflammation Mediators
  • Lipids
  • Tumor Suppressor Protein p53
  • Cyclin D1
  • Cyclin-Dependent Kinase Inhibitor p27
  • Insulin-Like Growth Factor I
  • eIF-2 Kinase
  • Glucose